Beyond Achondroplasia

Growing together with Clara

June 25, 2017
by inesp.alves

Therachon heading to Phase 1 clinical trial

Therachon’s medicine in development for achondroplasia, TA-46, was granted Orphan Drug designation by the medicine agencies FDA and EMA. TA-46 is a type 3 fibroblast growth factor receptor antagonist addressing achondroplasia. This medicine is an inactive form of the receptor that … Continue reading

March 4, 2016
by inesp.alves

Science with no results shared

One very important issue around clinical trials and many research projects (many are funded by public money) is that, at the end, the data and results are not published. In the site, when searching for studies in achondroplasia, it … Continue reading

May 26, 2014
by inesp.alves

The ECRAN/ECRIN meeting

The ECRAN/ECRIN meeting was very enlightening. I meet new people, from all over Europe, USA and Canada and heard their experience, knowledge and concerns about clinical trials. The presentations were pleasant, but others were quite disturbing, because many questions around … Continue reading

Translate »